Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.9305
Nov 20 • 3:59 PM ET Dollar change-0.0219 Percentage change(-2.30%)
Aftermarket Close
0.9301
Aftermarket • 7:41 PM ET Dollar change-0.0004 Percentage change(-0.04%)
Index
RUT
Market Cap
89.63M
Enterprise Value
-98.02M
Income
-122.23M
Sales
0.00M
Book/sh
1.84
Cash/sh
1.95
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
40
IPO
Sep 03, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.50
P/C
0.48
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
11.29
Current Ratio
11.29
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-1.25
EPS next Y
-0.77
EPS next Q
-0.20
EPS this Y
21.75%
EPS next Y
7.18%
EPS next 5Y
10.02%
EPS past 3/5Y
80.48% -
Sales past 3/5Y
- -
EPS Y/Y TTM
-76.37%
Sales Y/Y TTM
-
EPS Q/Q
4.58%
Sales Q/Q
-
Insider Own
47.45%
Insider Trans
0.00%
Inst Own
53.70%
Inst Trans
-4.40%
ROA
-72.21%
ROE
-85.51%
ROIC
-68.80%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-63.76%
SMA50
-73.71%
SMA200
-81.21%
Trades
Shs Outstand
96.31M
Shs Float
50.62M
52W High
7.44 -87.49%
52W Low
0.92 0.86%
Volatility
11.23% 14.55%
ATR (14)
0.39
RSI (14)
24.24
Beta
0.42
Rel Volume
1.10
Avg Volume
4.35M
Volume
4,773,895
Perf Week
-24.96%
Perf Month
-73.64%
Perf Quarter
-85.23%
Perf Half Y
-78.66%
Perf YTD
-82.24%
Perf Year
-74.65%
Perf 3Y
-79.18%
Perf 5Y
-90.60%
Perf 10Y
-
Prev Close
0.95
Price
0.93
Change %
-2.30%
Consensus
Strong Buy
Avg. Price Target
$8.33
Implied Upside
+795.2%
Analysts10incl. previous ratings
Rating Distribution9 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 08, 2026Initiated
WWilliam Blair
Outperform
Feb 09, 2026Initiated
WWedbush
Outperform$15+1,512.0%
Nov 04, 2024Initiated
LLeerink Partners
Outperform$15+1,512.0%
Sep 05, 2024Initiated
HH.C. Wainwright
Neutral$5+437.3%
May 03, 2024Initiated
PPiper Sandler
Overweight$26+2,694.2%
Oct 10, 2023Initiated
LLadenburg Thalmann
Buy$10+974.7%
Aug 25, 2023Initiated
OPY logoOOppenheimer
Outperform$17+1,727.0%
Jun 22, 2023Initiated
GGuggenheim
Buy$20+2,049.4%
Jun 14, 2023Initiated
CChardan Capital Markets
Buy$14+1,404.6%
May 24, 2023Initiated
RJF logoRRaymond James
Strong Buy$20+2,049.4%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SOMEIT SIDHUDirectorAug 18 '26Proposed Sale5.7550,000287,712Aug 18 05:52 PM
SOMEIT SIDHUDirectorAug 17 '26Proposed Sale5.6127,000151,343Aug 17 05:41 PM
SOMEIT SIDHUDirectorAug 14 '26Proposed Sale5.5140,000220,540Aug 14 04:36 PM
SOMEIT SIDHUDirectorAug 13 '26Proposed Sale5.6351,000287,043Aug 13 05:08 PM
AI Biotechnology LLC10% OwnerFeb 26 '26Buy6.252,000,00012,500,0006,552,725Mar 02 05:55 PM
Zura Bio Ltd. is a clinical-stage, multi-asset immunology company, which engages in the development of novel medicines for immune disorders. It focuses on the development of ZB-168, a treatment for Alopecia Areata and other inflammatory diseases. The company was founded by Someit Sidhu on January 18, 2022 and is headquartered in Henderson, NV.
Co-FounderDr. Sandeep Chidambar Kulkarni M.D.
COOMs. Kimberly Ann Davis J.D.
Ph.D.Dr. Kiran Nistala MBBS
VP of Finance & Accounting and Principal Financial & Accounting OfficerMs. Marlyn Mathew
Chief Technology OfficerDr. Gary Whale Ph.D.